Desta Z - Search Results

1

Desta Z, El-Boraie A, Gong L, Somogyi AA, Lauschke VM, Dandara C, Klein K, Miller NA, Klein TE, Tyndale RF, Whirl-Carrillo M, Gaedigk A. Desta Z, et al. Clin Pharmacol Ther. 2021 Jul;110(1):82-97. doi: 10.1002/cpt.2166. Epub 2021 Mar 11. Clin Pharmacol Ther. 2021. PMID: 33448339 Free PMC article. Review.

2

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. Ward BA, et al. Among authors: desta z. J Pharmacol Exp Ther. 2003 Jul;306(1):287-300. doi: 10.1124/jpet.103.049601. Epub 2003 Apr 3. J Pharmacol Exp Ther. 2003. PMID: 12676886

3

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, Zanger UM. Desta Z, et al. Pharmacogenomics. 2007 Jun;8(6):547-58. doi: 10.2217/14622416.8.6.547. Pharmacogenomics. 2007. PMID: 17559344

4

Antiestrogen pathway (aromatase inhibitor).

Desta Z, Nguyen A, Flockhart D, Skaar T, Fletcher R, Weinshilboum R, Berlin DS, Klein TE, Altman RB. Desta Z, et al. Pharmacogenet Genomics. 2009 Jul;19(7):554-5. doi: 10.1097/FPC.0b013e32832e0ec1. Pharmacogenet Genomics. 2009. PMID: 19512956 Free PMC article. No abstract available.

5

Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo.

Xu C, Ogburn ET, Guo Y, Desta Z. Xu C, et al. Among authors: desta z. Drug Metab Dispos. 2012 Apr;40(4):717-25. doi: 10.1124/dmd.111.042416. Epub 2012 Jan 9. Drug Metab Dispos. 2012. PMID: 22232427 Free PMC article.

6

Regulation of microRNA expression by rifampin in human hepatocytes.

Ramamoorthy A, Liu Y, Philips S, Desta Z, Lin H, Goswami C, Gaedigk A, Li L, Flockhart DA, Skaar TC. Ramamoorthy A, et al. Among authors: desta z. Drug Metab Dispos. 2013 Oct;41(10):1763-8. doi: 10.1124/dmd.113.052886. Epub 2013 Aug 9. Drug Metab Dispos. 2013. PMID: 23935064 Free PMC article.

7

PharmGKB summary: tamoxifen pathway, pharmacokinetics.

Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. Klein DJ, et al. Among authors: desta z. Pharmacogenet Genomics. 2013 Nov;23(11):643-7. doi: 10.1097/FPC.0b013e3283656bc1. Pharmacogenet Genomics. 2013. PMID: 23962908 Free PMC article. Review. No abstract available.

8

PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.

Lowenberg D, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. Lowenberg D, et al. Among authors: desta z. Pharmacogenet Genomics. 2014 Feb;24(2):133-8. doi: 10.1097/FPC.0000000000000019. Pharmacogenet Genomics. 2014. PMID: 24401834 Free PMC article. No abstract available.

9

Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes.

Benson EA, Eadon MT, Desta Z, Liu Y, Lin H, Burgess KS, Segar MW, Gaedigk A, Skaar TC. Benson EA, et al. Among authors: desta z. Front Pharmacol. 2016 Apr 26;7:111. doi: 10.3389/fphar.2016.00111. eCollection 2016. Front Pharmacol. 2016. PMID: 27199754 Free PMC article.

10

Variants in the CYP2B6 3'UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs.

Burgess KS, Ipe J, Swart M, Metzger IF, Lu J, Gufford BT, Thong N, Desta Z, Gaedigk R, Pearce RE, Gaedigk A, Liu Y, Skaar TC. Burgess KS, et al. Among authors: desta z. Clin Pharmacol Ther. 2018 Jul;104(1):130-138. doi: 10.1002/cpt.892. Epub 2017 Oct 25. Clin Pharmacol Ther. 2018. PMID: 28960269 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

183 results

Search Page